Home › Funds › TOWERVIEW LLC › CRVS

TOWERVIEW LLC position in CRVS

CORVUS PHARMACEUTICALS INC · Health Care

TOWERVIEW LLC reported holding 70,000 shares of CRVS (CORVUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$806K, representing 0.59% of its reported portfolio and ranking #12 among its reported holdings. TOWERVIEW LLC has disclosed CRVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)70.00K sh
Reported value held$806.40K
Portfolio Weight0.59%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How TOWERVIEW LLC's CRVS position evolved

TOWERVIEW LLC first disclosed a stake in CRVS in Q3 2023 at 342,478 shares (US$500K). The position peaked in Q3 2025 at 170,000 shares, worth US$1.3M. Across 13 filings, TOWERVIEW LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 70,000 shares valued at US$806K. Notable position changes include a 71% trim in Q3 2024 (shares rose 1% over the following quarter), a 65% increase in Q1 2025 (shares rose 26% over the following quarter), a 50% trim in Q1 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 342.48K $500.02K New
Q4 2023 436.87K $768.90K Add
Q1 2024 382.50K $680.85K Reduce
Q2 2024 400.00K $728.00K Add
Q3 2024 117.50K $620.40K Reduce
Q4 2024 77.50K $414.62K Reduce
Q1 2025 127.50K $405.45K Add
Q2 2025 170.00K $680.00K Add
Q3 2025 170.00K $1.25M Hold
Q4 2025 140.00K $1.08M Reduce
Q1 2026 70.00K $1.02M Reduce
Q2 2026 70.00K $1.05M Hold
Q3 2026 70.00K $806.40K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRVS and 13F data

CRVS (CORVUS PHARMACEUTICALS INC) is a Health Care company. 67 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRVS

All CRVS fund holders →

FAQ

How long has TOWERVIEW LLC held CRVS?

TOWERVIEW LLC has disclosed CRVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is TOWERVIEW LLC's current position in CRVS?

As of Q3 2026, TOWERVIEW LLC holds 70.00K shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $806.40K, representing 0.59% of its reported portfolio and ranking #12.

Has TOWERVIEW LLC been buying or selling CRVS?

In the latest 13F filing (Q3 2026), TOWERVIEW LLC held unchanged its position in CRVS. The position peaked in Q3 2025 at 170.00K shares.

Which other funds hold CRVS?

Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, PERCEPTIVE ADVISORS LLC, among 67 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.